Drug Type Biosimilar, Monoclonal antibody |
Synonyms Trastuzumab biosimilar, TQ-B211, 赛妥 |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (25 Jul 2023), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HER2 Positive Breast Cancer | CN | 25 Jul 2023 | |
HER2-positive gastric cancer | CN | 25 Jul 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Early Stage Breast Carcinoma | Phase 1 | CN | 08 Oct 2023 | |
Metastatic breast cancer | Phase 1 | CN | 08 Oct 2023 | |
Metastatic Gastric Carcinoma | Phase 1 | CN | 08 Oct 2023 |
Phase 3 | 386 | TQ-B211 | oapqixsscb(pviljebzix) = lvycixranh rrlsauxckg (xvswhqcvfp, 78.65 - 89.06) View more | Positive | 05 Dec 2023 | ||
Herceptin | oapqixsscb(pviljebzix) = jxeskwdnxf rrlsauxckg (xvswhqcvfp, 72.56 - 84.15) View more |